Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis

Area of Science:

• Immunology
• Neuroscience
• Pharmacology

Background:

• Interferon (IFN)-beta is a standard treatment for multiple sclerosis (MS), reducing disease activity.
• The mechanisms by which IFN-beta exerts its therapeutic effects, particularly regarding T-lymphocyte trafficking into the central nervous system (CNS), are not fully elucidated.
• Chemokine receptors on CD4(+) T-lymphocytes play a crucial role in directing their migration and influencing CNS inflammation in MS.

Purpose of the Study:

• To investigate the in vivo effects of IFN-beta treatment on the expression of chemokine receptors on CD4(+) T-lymphocytes in MS patients.
• To determine how these changes in chemokine receptor expression correlate with T-helper cell gene expression and plasma chemokine levels.
• To differentiate between acute and steady-state effects of IFN-beta on immune cell trafficking markers.

Main Methods:

• Flow cytometry was used to analyze the surface expression of chemokine receptors (CCR4, CCR5, CCR7, CXCR3) on CD4(+) T-lymphocytes.
• Enzyme-linked immunosorbent assay (ELISA) and real-time polymerase chain reaction (PCR) were employed to measure plasma chemokine levels and gene expression in blood mononuclear cells.
• Blood samples were collected at different time points relative to IFN-beta injections to distinguish acute versus steady-state effects.

Main Results:

• IFN-beta treatment led to increased steady-state expression of CCR4, CCR5, and CCR7 on CD4(+) T-cells after 3 months, while CXCR3 expression remained unchanged.
• Conversely, acute IFN-beta administration (9-12 hours post-injection) resulted in reduced CXCR3 expression, with no change in CCR4, CCR5, or CCR7.
• Untreated MS patients exhibited significantly lower CCR4 expression on CD4(+) T-cells compared to healthy volunteers. CXCL10 was the only plasma chemokine significantly increased by IFN-beta.
• CCR5 mRNA correlated with T-helper type 1 (Th1) genes, while CCR4 and CCR7 mRNA correlated with Th2 and immunoregulatory genes.

Conclusions:

• IFN-beta treatment induces steady-state increases in chemokine receptors crucial for CD4(+) T-lymphocyte trafficking, potentially facilitating CNS migration in MS.
• A key therapeutic benefit of IFN-beta may involve normalizing the reduced Th2-related CD4(+) T-cell CCR4 expression observed in MS patients.
• The timing of blood sampling relative to IFN-beta injections is critical for interpreting changes in chemokine receptor expression and CXCL10 levels.